| Ytd | -4.79% | |
| 1y | 257.23% |
| Open | 18.43 | Prev Close | 18.48 | Low | 17.23 | High | 18.99 | Mkt Cap | 908.86M |
| Vol | 1.85M | Avg Vol | 1.94M | EPS | -5.57 | P/E | N/A | Forward P/E | -6.89 |
| Beta | 0.82 | Short Ratio | 5.22 | Inst. Own | 76.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 16.09 | 200-d Avg | 15.84 | 1yr Est | 45.25 |
Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to de
WAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical st
Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to de
Top Wall Street analysts changed outlook on top names. Find all rating changes on Benzinga's ana
Wall Street analysts upgraded EDU, MKTX, and FORM stocks. Check out their ratings on Benzinga's
Wall Street analysts downgrade ADBE and SAIL, cutting price targets. Check other analysts' views
Top Wall Street analysts changed their outlook on top names. See analyst rating changes for PepsiCo,
B of A Securities analyst Alec Stranahan initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) w